Q-Line Biotech Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Manufacturing: 67.4% • Trading: 32.6%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Operating margins have improved to 27.1% from 19.6%
- Attractively priced for its growth - PEG of 0.8
CONS
- Receivables are growing faster than sales - a possible quality concern
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.10x)
- Free cash flow has been persistently negative
- Equity base is being diluted - shares outstanding up 933.3%
- Working capital days have increased from 100 to 135 days
- Total debt has risen sharply - up 35.6% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LENSKART | 681.75 | 180.93 | 118577.20 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| POLYMED | 1737.35 | 55.89 | 17610.03 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| MOLBIO | 1441.60 | 99.72 | 16613.00 | 0.00 | 527.44 | — | 4083.76 | — | 19.79 | 24.63 |
| QLINE | 726.20 | 30.40 | 1694.09 | 0.00 | — | — | — | — | 22.23 | — |
| 3BBLACKBIO | 1423.95 | 22.01 | 1222.13 | 0.35 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| LAXMIDENTL | 201.95 | 35.98 | 1111.32 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| GKB | 63.70 | 9.90 | 32.11 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
No quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 183 | 204 | 313 | 342 | |
| 149 | 166 | 252 | 244 | |
| Operating Profit | 34 | 38 | 62 | 98 |
| OPM % | 18.47% | 18.69% | 19.68% | 28.71% |
| 2 | 3 | -5 | 5 | |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| Profit before Tax | 30 | 31 | 35 | 73 |
| Tax % | 28.34% | 29.28% | 54.86% | 23.20% |
| Net Profit | 21 | 22 | 16 | 56 |
| EPS | 20.38 | 218.73 | 121.98 | 34.24 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 23%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 20%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 16%
- Last Year:
- 26%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| 126 | 160 | 188 | 230 | |
| 69 | 86 | 141 | 188 | |
| Trade Payables | 40 | 59 | 56 | 52 |
| 15 | 32 | 68 | 72 | |
| Total Liabilities | 251 | 339 | 455 | 558 |
| 23 | 60 | 74 | 142 | |
| Capital Work in Progress | 12 | 19 | 59 | 15 |
| 16 | 29 | 18 | 17 | |
| 44 | 105 | 90 | 95 | |
| 0 | 26 | 83 | 126 | |
| Cash & Bank | 90 | 30 | 47 | 76 |
| 67 | 69 | 84 | 87 | |
| Total Assets | 251 | 339 | 455 | 558 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 37 | -24 | 17 | 16 | |
| Cash from Investing | -26 | -45 | -77 | -29 |
| Cash from Financing | 26 | 17 | 53 | 42 |
| 25 | -52 | -7 | 29 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for QLINE
Loading news…
AI Stock Analyst
Q-Line Biotech Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account